Talazoparib (BMN 673) in Advanced Solid Tumors with BRCA Mutations

Phase 2, open-label, single-arm trial of talazoparib in ovarian cancer, breast cancer, primary peritoneal cancer (PPC) and 4 more, sponsored by National Cancer Institute. Primary endpoint: Percent of Participants Who Achieve a Sustained Progressive Disease (PD) Response, Defined to be at Least 4% Nuclear Area Positive (NAP) γH2AX at the Day 8 Biopsy. Started Feb 2014; status: completed.